PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Johannes Duell, Pau Abrisqueta, Martin Dreyling, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Kami Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Open source

DOI: 10.1097/01.hs9.0000975944.73895.05
Published: 8
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000975944.73895.05,
  title = {PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA},
  author = {Johannes Duell and Pau Abrisqueta and Martin Dreyling and Gianluca Gaidano and Eva González Barca and Wojciech Jurczak and Anna Marina Liberati and Kami Maddocks and Tobias Menne and Zsolt Nagy and Olivier Tournilhac and Abhishek Bakuli and Aasim Amin and Konstantin Gurbanov and Gilles Salles},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000975944.73895.05},
  url = {https://doi.org/10.1097/01.hs9.0000975944.73895.05}
}

RIS

TY  - JOUR
TI  - PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
AU  - Johannes Duell
AU  - Pau Abrisqueta
AU  - Martin Dreyling
AU  - Gianluca Gaidano
AU  - Eva González Barca
AU  - Wojciech Jurczak
AU  - Anna Marina Liberati
AU  - Kami Maddocks
AU  - Tobias Menne
AU  - Zsolt Nagy
AU  - Olivier Tournilhac
AU  - Abhishek Bakuli
AU  - Aasim Amin
AU  - Konstantin Gurbanov
AU  - Gilles Salles
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000975944.73895.05
UR  - https://doi.org/10.1097/01.hs9.0000975944.73895.05
ER  -

APA

Duell, J., Abrisqueta, P., Dreyling, M., Gaidano, G., Barca, E. G., Jurczak, W., Liberati, A. M., Maddocks, K., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., & Salles, G. (2023). PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. HemaSphere. https://doi.org/10.1097/01.hs9.0000975944.73895.05

Source records

doaj · retrieved 2026-09-26T12:37:48.664Z